Opioids before and after initiation of pregabalin in patients with diabetic peripheral neuropathy

Current Medical Research and Opinion

Volumn 28, Issue 9, 2012, Pages 1485-1496

  Kozma, Chris M ^a   Benson, Carmela ^b   Slaton, Terra L ^a   Kim, Myoung S ^b   Vorsanger, Gary J ^b  

^a LCC ^*

^b LCC   (United States)

Author keywords

Diabetic neuropathies; Opioids; Pain; Pregabalin

Indexed keywords

OPIATE; PREGABALIN;

ADULT; AGED; ARTHRITIS; ARTHROPATHY; ARTICLE; AUTONOMIC NEUROPATHY; BACKACHE; CARPAL TUNNEL SYNDROME; CAUSALGIA; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC PERIPHERAL NEUROPATHY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; FACE PAIN; FEMALE; HEALTH INSURANCE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; NECK PAIN; NEURITIS RADICULITIS; NEUROPATHIC PAIN; OSTEOARTHRITIS; OUTPATIENT; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHANTOM PAIN; POLYNEUROPATHY; PRESCRIPTION; RADICULITIS; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; TRIGEMINUS NEURALGIA;

EID: 84866680489     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.713338     Document Type: Article

References (35)

1. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28:956-62
2. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 (http://www.cdc.gov/diabetes/pubs/factsheet11.htm). Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
3. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2003 (http://www.cdc.gov/diabetes/pubs/factsheet03.htm). Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, 2004
4. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 2002;25:2048-52
5. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006;29:1518-22
6. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009;35:206-13
7. Possidente CJ, Tandan R. A survey of treatment practices in diabetic peripheral neuropathy. Prim Care Diabetes 2009;3:253-7
8. Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76:1758-65
9. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324-34
10. Gatti A, Sabato AF, Occhioni R, et al. Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. Eur Neurol 2009;61:129-37
11. Diabetic peripheral neuropathic pain. Consensus guidelines for treatment. J Fam Pract 2006;Suppl:3-19
12. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:S3-14
13. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004;5:143-9
14. Berger A, Dukes E, McCarberg B, et al. Change in opioid use after the initiation of gabapentin therapy in patients with postherpetic neuralgia. Clin Ther 2003;25:2809-21
15. Gore M, Sadosky A, Tai KS, Stacey B. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Clin Ther 2007;29:1655-70
16. Berger A, Sadosky A, Dukes E, et al. Use of pregabalin in patients with painful neuropathic disorders under the care of general practitioners in the U.K. Pain Pract 2009;9:18-34
17. Kirson NY, Ivanova JI, Birnbaum HG, et al. Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. J Med Econ 2010;13:482-91
18. Margolis J, Cao Z, Fowler R, et al. Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine. J Med Econ 2010;13:738-47
19. Chen S, Wu N, Fraser K, et al. Opioid use and healthcare costs among patients with DPNP initiating duloxetine versus other treatments. Curr Med Res Opin 2010;26:2507-16
20. Wu N, Chen SY, Hallett LA, et al. Opioid utilization and health-care costs among patients with diabetic peripheral neuropathic pain treated with duloxetine vs. other therapies. Pain Pract 2011;11:48-56
21. Gore M, Tai KS, Zlateva G, et al. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin. Pain Pract 2011;11:528-39
22. Zhao Y, Sun P, Watson P. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin. Curr Med Res Opin 2011;27:785-92
23. MarketScan® User Guide. Commercial Claims and Encounters Medicare Supplemental and Coordination of Benefits, Data Year 2007. Englewood, CO: Thompson Healthcare Inc., 2007
24. Lyrica (pregabalin) Prescribing Information. New York: Pfizer Inc., 2011
25. Niscola P, Scaramucci L, Vischini G, et al. The use of major analgesics in patients with renal dysfunction. Curr Drug Targets 2010;11:752-8
26. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology 2010;112:810-33
27. Pfizer reports top-line results from phase 3 trial of Lyrica (pregabalin) capsules CV in patients with inadequately treated painful diabetic peripheral neuropathy. New York: Pfizer Inc., 2012 [cited 2012 May 8]; Available from: http://www.pfizer.com/news/press-releases/pfizer-press-release. jsp?guid=20120504005287en
28. Pfizer stops phase 3 trial of Lyrica (pregabalin) capsules CV in neuropathic pain associated with HIV neuropathy. New York: Pfizer Inc., 2012 [cited 2012 May 8]; Available from: http://www.pfizer.com/news/press-releases/ pfizer-press-release.jsp?guid=20120504005201en
29. Hanna M, O'Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 2008;12:804-13
30. Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004;22:2909-17
31. Zin CS, Nissen LM, O'Callaghan JP, et al. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. J Pain 2010;11:462-71
32. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-9
33. Gianni W, Ceci M, Bustacchini S, et al. Opioids for the treatment of chronic non-cancer pain in older people. Drugs Aging 2009;26(Suppl1):63-73
34. Auret K, Schug SA. Underutilisation of opioids in elderly patients with chronic pain: approaches to correcting the problem. Drugs Aging 2005;22:641-54
35. Morley-Forster PK, Clark AJ, Speechley M, Moulin DE. Attitudes toward opioid use for chronic pain: a Canadian physician survey. Pain Res Manag 2003;8:189-94